Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Fluvoxamine  COVID-19 treatment studies for Fluvoxamine  C19 studies: Fluvoxamine  Fluvoxamine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  

Fluvoxamine for COVID-19: real-time meta analysis of 17 studies

Covid Analysis (Preprint) (meta analysis)
Covid Analysis, Fluvoxamine for COVID-19: real-time meta analysis of 17 studies, (Preprint) (meta analysis)
Jun 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
• Statistically significant improvements are seen for mortality, hospitalization, and cases. 11 studies from 11 independent teams in 6 different countries show statistically significant improvements in isolation (5 for the most serious outcome).
• Meta analysis using the most serious outcome reported shows 38% [19‑52%] improvement. Results are slightly worse for Randomized Controlled Trials and similar for peer-reviewed studies.
• Results are robust — in exclusion sensitivity analysis 9 of 17 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.
• Treatment recommendations are available from Ontario.
• No treatment, vaccine, or intervention is 100% effective and available. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments may be more effective. Only 12% of fluvoxamine studies show zero events with treatment.
• All data to reproduce this paper and sources are in the appendix. Other meta analyses for fluvoxamine can be found in [Deng, Lee, Lu, Marcec, Nakhaee], showing significant improvements for mortality, hospitalization, and severity.
Percentage improvement with fluvoxamine (more)
Late treatmentEarly treatmentAll studiesStudies Patients Authors
All studies51% [25‑68%]**43% [-10‑70%]38% [19‑52%]*** 1736,705 414
Randomized Controlled TrialsRCTs32% [-22‑62%]28% [-17‑56%]30% [-1‑51%] 85,739 337
Mortality51% [22‑69%]**65% [-1506‑99%]41% [8‑62%]* 84,224 130
HospitalizationHosp.22% [-3‑41%]37% [-4‑61%]25% [6‑40%]* 106,384 356
Cases--25% [11‑36%]*** 29,116 10
RCT mortality30% [-26‑63%]-200% [-7253‑88%]27% [-33‑60%] 22,973 62
Covid Analysis et al., Jun 2023, preprint, 1 author.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFluvoxamineAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit